Reddys, Cipla Demand has been reinforced by payer shifts, expanding telehealth-based prescriptions, and elevated interest in GLP1 receptor agonists as a non-invasive alternative to bariatric procedures
linagliptin needs no renal adjustment Limitations & safety Cardiovascular outcome trials (CVOTs) PBS rules (Authority Required Streamlined) Must be used with metformin sulfonylurea and/or insulin
The findings were compelling, tirzepatide not only achieved greater reductions in HbA1c but also delivered significant body weight loss, all while showing a lower incidence of hypoglycemia at the 52-week mark
Authors relationships and activities LJ reports receiving consulting and lecture fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck, MSD, Novo Nordisk, Roche and Sanofi-Aventis